Fecal pyruvate kinase-M2 (Tumor M2-PK) measurement: A new screening concept for colorectal cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1949-1952

  Ewald, Nils ^a   Schaller, Markus ^a   Bayer, Martin ^a   Akinci, Ahmet ^a   Bretzel, Reinhard G ^a   Kloer, Hans Ulrich ^a   Hardt, Philip D ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Colorectal cancer; Stool; Tumor M2 PK; Tumor screening

Indexed keywords

PYRUVATE KINASE M2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; ENTERITIS; FECES ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; COLORECTAL NEOPLASMS; FECES; HUMANS; MASS SCREENING; MIDDLE AGED; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250705192     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A and Edwards BK (eds.): SEER Cancer Statistics Review: 1973-1994. Bethesda, MD National Cancer Institute, 1997.
2. Lamberti C and Sauerbruch T: Frühdiagnostik kolorektaler Tumorleiden. Internist 46: 401-410, 2005.
3. Mandel JS, Church TR, Ederer F and Bond JH: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91: 434-437, 1999.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD and Sondergaard O: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467-1471, 1996.
5. Jorgensen OD, Kronborg O and Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50: 29-32, 2002.
6. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD and Mangham CM: Randomised controlled trial of faecal occult- blood screening for colorectal cancer. Lancet 348: 1472-1477, 1996.
7. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC and Schuman LM: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343: 1603-1607, 2000.
8. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H and Kloer HU: Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20(6D): 4965-4968, 2000.
9. Haug U, Rothenbacher D, Hardt PD, Kloer HU, Stegmaier C and Brenner H: Tumor M2-PK: a promising method for colorectal cancer screening. J Cancer Res Clin Oncol 130: 172, 2004.
10. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E and Kloer HU: Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91(5): 980-984, 2004.
11. Hardt PD, Toepler M, Ngoumou B, Rupp J and Kloer HU: Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 23(2A): 851-853, 2003.
12. Koss K, Maxton D and Jankowski J: The potential use of fecal dimeric M2 pyruvate kinase (tumour M2-PK) in screening for colorectal cancer. Gut 54: 20, 2005.
13. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M and Moslein G: Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 130(14): 872-877, 2005.
14. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF and Stein J: Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochensch 129(34-35): 1806-1807, 2004.
15. Alquist, DA, McGill DB, Schwartz S, Taylor W and Owen RA: Fecal blood levels in health and disease. N Engl J Med 312: 1422-1428, 1985.
16. Towler BP, Irwig L, Glasziou P, Weller D and Kewenter J: Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2: 1216, 1998.
17. Young GP and St. John DJ: Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointest Res 18: 135-156, 1991.
18. Davies RJ, Miller R and Coleman N: Colorectal cancer screening: prospects for molecular stool analysis? Nat Rev Cancer 5(3): 199-209, 2005.
19. Macrae FA and St. John DJ: Relationship between patterns of bleeding and haemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 82: 891-898, 1982.
20. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schumann LM and Ederer F: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371, 1993.
21. Frattini M, Balestra D, Pilotti S, Bertario L and Pierotti MA: Tumor location and detection of k-ras mutations in stool from colorectal cancer patients. J Natl Cancer Inst 95: 72-73, 2003.
22. Eguchi S, Kohara N, Komuta K and Kanematsu T: Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 77(Suppl. 8): 1707-1710, 1996.
23. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, Hamilton SR, Boynton K, Kinzler KW and Vogelstein B: Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 346: 311-320, 2002.
24. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, Boynton K, Kinzler KW and Vogelstein B: Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 359: 403-404, 2002.